Earnings Releases·Oct 29, 2026, 4:02 PM ET

CareDx — Third Quarter 2026 Earnings Summary

Total revenue reached $139 million, a 39% year-over-year increase, driven by a 65% surge in Testing Services revenue to $119 million and a 31% rise in Patient and Digital Solutions to $20 million.
Profitability metrics expanded significantly with GAAP net income rising to $19 million from $2 million in the prior year period, while Adjusted EBITDA doubled to $30 million with a 22% margin.
Full-year 2026 guidance was raised to $520–$530 million for revenue and $90–$100 million for Adjusted EBITDA, reflecting strong execution and the inclusion of $12 million in Specialty Oncology revenue from the NavDx acquisition.
Strategic milestones include the completed acquisition of Naveris, Inc. for up to $260 million, the divestiture of the Lab Products business, and the advancement of AlloHeme and HistoMap Kidney toward commercial launch and CLIA readiness in 2027.
The company ended the quarter with $250.5 million in cash and cash equivalents, up from $65.4 million at the start of the year, supporting continued investment in pipeline development and market expansion.